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Abstract  
Background 
Measures that reflect patients’ assessment of their health are of increasing importance as 
outcome measures in randomised controlled trials. The methodological approach used in the 
pre-validation development of new instruments (item generation, item reduction and 
question formatting) should be robust and transparent. The totality of the content of existing 
PRO instruments for a specific condition provides a valuable resource (pool of items) that 
can be utilised to develop new instruments. Such ‘top down’ approaches are common, but 
the explicit pre-validation methods are often poorly reported. This paper presents a 
systematic and generalisable 5-step pre-validation PRO instrument methodology.  
Methods 
The method is illustrated using the example of the Aberdeen Glaucoma Questionnaire 
(AGQ). The five steps are: 1) Generation of a pool of items; 2) Item de-duplication (three 
phases); 3) Item reduction (two phases); 4) Assessment of the remaining items’ content 
coverage against a pre-existing theoretical framework appropriate to the objectives of the 
instrument and the target population (e.g. ICF); and 5) qualitative exploration of the target 
populations’ views of the new instrument and the items it contains.  
Results 
The AGQ ‘item pool’ contained 725 items. Three de-duplication phases resulted in 
reduction of 91, 225 and 48 items respectively. The item reduction phases discarded 70 
items and 208 items respectively.  The draft AGQ contained 83 items with good content 
coverage. The qualitative exploration (‘think aloud’ study) resulted in removal of a further 
15 items and refinement to the wording of others. The resultant draft AGQ contained 68 
items.  
Conclusions 
This study presents a novel methodology for developing a PRO instrument, based on three 
sources: literature reporting what is important to patient; theoretically coherent framework; 
and patients’ experience of completing the instrument. By systematically accounting for all 
items dropped after the item generation phase, our method ensures that the AGQ is 
developed in a transparent, replicable manner and is fit for validation. We recommend this 
method to enhance the likelihood that new PRO instruments will be appropriate to the 
research context in which they are used, acceptable to research participants and likely to 
generate valid data. 
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Background  
Measures that reflect patients’ assessment of their health are of increasing importance as 
outcome measures in randomised controlled trials (RCTs). The decision whether to use a 
validated patient reported outcome (PRO) instrument or to develop a new one should be 
based on a thorough review of PRO instruments used in a population of interest [1]. If a new 
PRO instrument is required, the methodological approach used in its development should be 
robust and transparent. There are two main phases in generating a new PRO instrument – 
developing the instrument and validating the instrument. Steps for developing a PRO 
instrument involve item generation, item reduction and question formatting.  Validation of 
the instrument follows, to assess coherence across the items and inform the removal of 
poorly discriminating, unreliable or invalid items [2].  
 
To generate a pool of potentially relevant items for condition-specific instruments, most 
studies focus on an inductive ‘bottom up’ approach using qualitative methods (e.g. focus 
groups or one-to-one interviews with the target population), which ensures items reflect the 
perspective of the majority of individuals in the population of interest [3, 4].  However, data 
generated using this approach often reaffirm previous qualitative findings, resulting in the 
development of ‘new’ instruments containing items with overlapping, but not identical 
content coverage [3, 4, 5].  
 
As the catalogue of validated PRO instruments grows within a clinical specialty, so does the 
body of empirical evidence of what is important to patients with that condition (‘content’ 
domains). The body of evidence represented by the totality of the content of existing PRO 
instruments for a specific condition may provide a valuable resource (pool of items) that can 
be utilised to develop new PRO instruments. Such ‘top down’ approaches, using expert 
opinion and/or the published literature in the field, are common [6] but the explicit methods 
used in the item generation and item reduction stages are often poorly reported [7, 8].  
 
To address the lack of explicit methods for item generation and reduction, this paper 
presents a 5-step methodology for the pre-validation stages of PRO instrument development 
(i.e. item generation, item reduction and question formatting). The method is illustrated 
using the example of the Aberdeen Glaucoma Questionnaire (AGQ), a new instrument 
designed to be used for  a future randomised controlled trial  (RCT) evaluating the 
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effectiveness of glaucoma screening compared with no formal screening (opportunistic case 
detection)  
 
Methods 
Example instrument – Aberdeen Glaucoma Questionnaire 
The aim of the AGQ is to compare patient reported vision related disability between the 
intervention (glaucoma screening) and comparator (opportunistic case detection) arms at the 
end of a proposed RCT. In ophthalmology there are high quality validated vision and 
glaucoma PRO instruments covering a wide range of content (e.g. visual impairment, visual 
symptoms, treatment satisfaction, activity and participation difficulties) [9]. However, 
existing instruments used in glaucoma populations are not suitable in their entirety for 
evaluating screening interventions because the trial population includes people with and 
without a diagnosis [9]. In addition, within a screening trial context it is also important to 
compare other health effects between the screened and unscreened population to capture any 
wider benefits or harms of screening. Existing generic instruments are adequate for this 
purpose and can be used alongside condition-specific measures. Given this context, we 
proposed to build on previous research by making use of the existing body of knowledge in 
terms of items that are known to be relevant to people with glaucoma and to develop a new 
instrument from these. 
 
Table 1 presents the five steps involved in the pre-validation PRO development 
methodology. Steps 1 to 3 involve the synthesis of the products of research (i.e. validated 
PRO instruments). The items that result from the systematic application of these steps form 
the basis of a new condition-specific PRO instrument. Step 4 involves assessment of the 
content coverage of items retained after Step 3 against a pre-existing theoretical framework 
appropriate to the objectives of the instrument and the target population. This process 
provides clarity on the dimensions of health covered in the new PRO instrument (i.e. how 
well the construct under measurement is represented by an instrument). Step 5 comprises a 
qualitative exploration of the target populations’ views of the new instrument and the items 
it contains.  
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1. Item generation for the AGQ 
a) We selected instruments from PRO instruments used in a glaucoma context (generic, 
vision- and glaucoma-specific) that had been systematically identified as part of a wider 
study assessing instrument quality [9] using the following eligibility criteria: suitable for self 
report; validated in a glaucoma population; in the public domain; items and response options 
fully described in the text article reporting the instrument. The total content of the selected 
instruments provided a comprehensive pool of items, relevant to people with glaucoma, 
from which to select the ‘best’ combination of items to meet the specific scope of a new 
instrument.   
b) The widely validated generic measure SF-36 was added to the list of selected instruments 
as it would be administered alongside the glaucoma-specific AGQ, in the proposed trial.  
c) A database consisting of all items from the selected instruments (item pool) was created 
with items grouped according to content (e.g. reading, driving, walking). All information 
relating to the instrument of origin, the item and response option content and wording was 
retained.  
 
2. Item de-duplication for the AGQ 
We conducted three phases of de-duplication (A, B, C) in the development of the draft    
AGQ.  
A) In the first de-duplication task, three pairs of reviewers from the multi-disciplinary 
research team (health services researchers, health psychologists and ophthalmologists) 
independently assessed one third of all items for literal duplications. Literal duplication was 
defined as identically worded items (including timeframe), or items which, in each 
reviewer’s opinion, asked the same question (but may be worded differently) and which, if 
both were included in the AGQ, would represent duplication of content. One researcher 
(MP) collated decisions from each pair of reviewers. Items for which there was reviewer 
agreement were reduced to a single item in the item pool, with all other information retained 
(i.e. instrument of origin, response options and unique item number). Any reviewer 
disagreements were resolved by consensus or arbitration by JB (clinical academic 
(ophthalmology)). 
 
B) The second phase of item de-duplication involved grouping together all items that 
referred to the same aspect of a specific content theme (e.g. loneliness), but which differed 
in timeframe or in whether they included an attribution of action to eyesight (e.g. do you feel 
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alone? versus in the past month have you felt lonely or isolated because of your eyesight?). 
Such items were grouped together and the wording of all individual items within each group 
was retained. The purpose of this phase of de-duplication was to retain all aspects of all 
content themes within the item pool, whilst acknowledging that only one item per group 
would ultimately be chosen for inclusion in the AGQ. 
 
C) The third phase of de-duplication identified item content overlap between the SF-36 
items and other items in the pool. All SF-36 items and any extra items considered, by the 
multi-disciplinary team, to be directly covered by SF-36 items were removed from the item 
pool.  
 
3. Item reduction for the AGQ 
Two phases of item reduction (D and E) were conducted to determine which items were 
retained in the draft AGQ.   
  
D) The first phase of item reduction consisted of a ‘macro level’ removal of items relating to 
content themes that were not appropriate for inclusion in the AGQ; a self-report measure of 
vision related disability. Decisions regarding the removal of all items within a content theme 
(e.g. treatment satisfaction) were informed by the literature and by the multi-disciplinary 
research team including the clinical opinion of the three ophthalmologists involved in the 
project.  
 
E) All items remaining after Phase D covered content themes (e.g. driving, reading, using 
public transport) relevant to vision related disability associated with glaucoma. However, the 
specific wording of many of these items made them unsuitable for inclusion in the draft 
AGQ. Explicit criteria were applied to identify items for removal. All items that were not 
applicable to people without a diagnosis of glaucoma were removed. As were items 
referring to ‘frequency of’ rather than ‘difficulty with’ performing an activity (e.g. driving). 
Items relating to very specific tasks (e.g. difficulty threading a needle) were removed to 
reduce participant burden and to accommodate the inclusion of similar, but more widely 
applicable items (e.g. difficulty with tasks that require you to see up close). Item quality was 
assessed by the multi-disciplinary team. Items with poor reading ease and/or potential 
ambiguity were removed (e.g. “Do you hit persons or objects?”). Following phase E of the 
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item reduction, the wording of the remaining items was adapted to maximise consistency of 
both item wording and response format. Items were then formatted as the draft AGQ.  
 
4. Assessing AGQ content coverage against a pre-existing theoretical framework 
We used the World Health Organisation (WHO) International Classification of Functioning, 
Disability and Health (ICF) [10] to assess the content coverage of the AGQ. The ICF 
provides a framework within which item content can be systematically coded using a 
standardised common language [10] thus providing clarity on how well the construct under 
measurement (i.e. vision related disability associated with glaucoma) is represented within 
the AGQ. The ICF takes into account the social aspects, not just the medical or biological 
aspects of disability, and defines four components of functioning and disability: Body 
Structures, Body Functions, Activities and Participation [10].  In addition, the ICF contains 
contextual Environmental Factors (i.e. physical, attitudinal and social factors) and Personal 
Factors (e.g. age, gender) that might influence functioning and disability. The content of 
each included item in the draft AGQ was assessed for its coverage of ICF components and 
contextual factors using the linking rules developed by Cieza and colleagues (2005) [11]. 
This process involves first identifying the meaningful concepts (i.e. the ideas or information) 
contained within each item in the AGQ. These might relate to body structures (e.g. the eye) 
or functions (e.g. seeing) or to activities (e.g. walking) or to participation in a life situation 
(e.g. using public transport). Each meaningful concept is then linked to the most precise ICF 
category and coded accordingly (e.g. visual field = b2101, light intensity = e2400) [10].  
 
5. Exploratory pilot work – A ‘think aloud’ study  
The ‘think aloud’ technique (cognitive interviewing) is a valuable method for gaining 
insights into people’s thought processes whilst undertaking a task [12]. The technique is 
commonly used during questionnaire development to determine whether the meaning of an 
item, as intended by the questionnaire developer, is consistent with the respondent’s 
interpretation of that item [13].  A ‘think aloud’ study was conducted to explore glaucoma 
patients’ views on the comprehensibility, acceptability, relevance and answerability of the 
draft AGQ in order to inform its refinement. Ethical approval was obtained from the North 
of Scotland Research Ethics Committee (Ref: 09/S0801/41) 
 
Participants consisted of a purposive sample of eight patients with differing severities of 
glaucoma (two each with mild, moderate or severe glaucoma and two with no visual 
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impairment). Each participant completed the AGQ, in the presence of a researcher (MC), 
who asked them to verbalise their thoughts (‘think aloud’) whilst completing a paper version 
of the draft AGQ. In addition, MC probed patients’ comments about specific items and 
ascertained their opinions about the AGQ in general (e.g. content, format, length). 
Interviews were audio-recorded and transcribed verbatim. Verbal responses to each item 
were tabulated alongside a participant’s written response to that item to identify possible 
impact of item interpretation on written responses. We used an ‘item centred’ coding 
scheme based on Tourangeau’s Cognitive Aspect of Survey Methodology Framework to 
identify ‘problem’ items (i.e. those with which participants had difficulty following 
instructions or problems with comprehensibility, acceptability, relevance or answerability) 
[14]. MC coded all transcripts and MP double coded two transcripts (25% of the data). 
Disagreements were resolved by consensus of the ‘think aloud’ research team (MC, MP, JF, 
JB). The ‘think aloud’ findings informed the refinement of the AGQ. 
 
Results  
Figure 1 presents an overview of the results in the development of the AGQ.  Each of the 
steps represented in Figure 1 is described in detail below. 
 
1. Item generation for the AGQ 
The systematic review of PRO instruments used in the glaucoma populations identified 34 
vision- or glaucoma-specific instruments and 7 generic instruments [9]. From these, we 
selected the 20 instruments (17 vision-specific, 3 generic) that met the selection criteria for 
inclusion in the item pool [15-34] (see Table 2). In addition, we included the SF-36 [35] in 
the selected instruments as it was to be an outcome measure in the proposed screening trial 
and including it allowed us to use these systematic methods to avoid duplication of content 
coverage between the SF-36 and items from other instruments.  
 
The deconstruction of eligible instruments and the SF-36 into constituent items generated an 
item pool of 725 items (Figure 1). When considered together, the total content of these 20 
instruments provides a large assortment of items relevant to people with glaucoma. An 
extract from the item pool is shown in Table 3. 
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2. Item de-duplication for the AGQ 
Phase A 
The literal duplication phase resulted in the reduction of 91 items. For example, Table 4 
shows that four instruments include the item “In general would you say your [overall] 
health is…”, although response options vary. The stems of these four items were reduced to 
a single item, creating a reduction of three items from the item total (Table 5). All other 
information about items 2, 3, 4 and 5 was retained (i.e. instrument of origin, response option, 
unique item identification).  
 
Phase B 
The grouping of items that refer to the same aspect of a specific content theme, but which 
differ in timescale or attribution of action to eyesight resulted in the reduction of 225 items. 
The wording of all such items was retained, but row borders between them were removed. 
For example, two of the three items in Table 6 include a timescale (153, 68) and Item 68 
asks participants to attribute any loneliness to their eyesight, whilst the other two do not. 
 
Phase C 
The third phase of item de-duplication resulted in the reduction of 48 items (Figure 1); the 
36 items from the SF-36 and 12 extra items considered to be directly covered by SF-36 
items were removed. For instance, whilst not a literal duplication or only differing in 
timescale and/or attribution, the SF-36 item on bathing and dressing was considered to 
directly cover three items on dressing from two other instruments (Table 7).   
 
3. Item reduction for the AGQ 
Phase D 
Decisions on which content themes were not relevant for inclusion in the AGQ were 
informed by the literature and by ophthalmologists on the research team. Excluded content 
themes include nausea, hearing, sleep, personal financial circumstances, treatment 
satisfaction and access to health services. This macro level item reduction (D) resulted in the 
removal of 70 items. 
 
Phase E 
The micro level reduction reduced the remaining 292 items to 83 items. Table 8 shows four 
such items removed in phase E. Although the content coverage of these items is relevant for 
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inclusion in the AGQ, they relate to the performance of very specific tasks and were 
removed to reduce participant burden and to accommodate the inclusion of other, more 
widely applicable, items. 
 
4. Linking AGQ content to the ICF 
The 83 items in the initial version of the AGQ originated from 16 of the 20 instruments used 
to generate the item pool in Step 1a [15, 18, 19, 21-27, 29-34]. The items contained 
meaningful concepts related to two ICF categories of Body Structure, eight of Body 
Function, fifteen categories associated with Activity or Participation and seven categories of 
Environmental factors. (See additional file 1: Linking AGQ content to ICF) 
 
Inevitably, with such a collection of 83 items, item timescales varied in the initial version of 
the AGQ, as did response formats and the use of first- and second-person personal pronouns. 
Fifty-three of the selected items were formatted as questions; the others as statements or 
symptom checklists. This eclectic mix of 83 items represented the ‘best’ combination of 
content coverage with appropriate theoretical coverage. Item stem and response option 
wording was adapted to increase consistency in the new instrument, but the content and 
theoretical coverage of each item accurately reflected the original (i.e. in terms of 
meaningful concept). It was this initial draft of the AGQ (with 83 items) that was subjected, 
in Step 5, to further investigation using the ‘think aloud’ technique. 
 
5. Results of Think Aloud study  
The think-aloud interviews resulted in the removal of fifteen items from the initial version of 
the AGQ. Seven of these were removed due to comprehensibility problems (i.e. the 
participant either reported difficulties with the meaning of words, or they answered the item 
in such a way that suggested the item was not understood, or they reported a lack of 
contextual information needed to answer the item accurately (e.g. lack of timeframe). 
Importantly, the ICF category coverage was not affected by the removal of these, or any 
other, items. Removal of a further four items resulted from participants’ suggestions of item 
redundancy (i.e. items covering difficulty with driving in different contexts were removed 
(e.g. driving in the rain at night with oncoming headlights) in the presence of five other 
driving items). The final four items removed resulted from the condensing of two-part items 
into single items following difficulties experienced by participants with correctly following 
re-routing instructions.  
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In addition to item removal, the think aloud study findings informed changes to the wording 
of retained items to increase consistency of item wording and minimise participant burden. 
For example in the initial version of the AGQ, the word difficulty appeared in many of the 
questions (do you have difficulty with…?), as well as in the corresponding response options 
(no difficulty, a little difficulty, moderate difficulty, extreme difficulty). The word difficulty 
was removed from the response options of such items, thus changing the wording of such 
responses to: no; a little; moderate; extreme. This change occurred in response to 
suggestions that the repetition in wording between question and response option was 
unnecessary and irritating.  
 
Summary of results 
The systematic identification of 20 self-report instruments used in a glaucoma population 
and in the public domain, together with the SF-36, generated a total of 725 items, with 
extensive content coverage, for inclusion in an item pool. The application of three phases of 
de-duplication and two phases of item reduction resulted in the removal of a total of 642 
items. The remaining 83 items were assessed to have a good breadth of coverage of ICF 
components (body structures, body functions, activity, participation and environment) and 
formed the initial draft of the AGQ. Where necessary the wording and formatting of items 
was adapted to increase consistency, but the content and theoretical coverage of each item 
was maintained.  The exploration of comprehensibility, acceptability, relevance and 
answerability of the initial draft of the AGQ in a ‘think aloud’ study resulted in the removal 
of 15 items and to the refinement of others. The resultant pre-validation draft AGQ contains 
68 items.     
Discussion  
 
This paper outlines a novel methodological approach that is applicable to situations where a 
systematic literature review has identified numerous high quality validated instruments 
(developed using mainly inductive methods), but where none of the identified instruments 
are appropriate to be used, in their current form, to address the research questions in a 
particular study.  Our method employs a systematic 5-step approach: 1) Generation of a pool 
of items from an existing body of knowledge; 2) Item de-duplication; 3) Item reduction; 4) 
Assessment of content validity (against a relevant pre-existing theoretical framework); and 
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5) Exploratory pilot work to assess comprehensibility, acceptability, relevance and 
answerability to the target population . Whilst our 5-step approach is largely ‘top down’, it 
differs from other studies using expert opinion and published literature to develop PRO 
instruments in that we systematically utilise the body of empirical evidence amassed from 
studies using ‘bottom up’ (qualitative) approaches.  
 
We illustrated our pre-validation method using the example of the AGQ; a new glaucoma-
specific PRO instrument for use as the primary patient reported outcome measure for a RCT 
evaluating the effectiveness of glaucoma screening. We describe how a large number of 
items representing the totality of the content of existing PRO instruments for a specific 
condition can be reduced to those included in a draft PRO instrument with appropriate 
content and theoretical coverage, and ready for validation. The methods we describe are 
applicable to the development of other PRO instruments and more widely to instrument 
development in other disciplines.  
 
This paper addresses a methodological gap in the pre-validation instrument development 
literature, where there is a tendency for authors to report, in some detail, the item generation 
phase that result from qualitative work [3, 5, 36]. However, there are few reports of how a 
large number of items generated in early phase work (using qualitative methods, expert 
opinion and/or published literature) are reduced to those that are included in the draft PRO 
instrument used in the validation process. 
 
The aim of the AGQ is to measure vision related disability associated with glaucoma and its 
treatment in a population screening trial. The use of the ICF as a theoretical framework 
enabled us to identify which aspects of vision related disability are covered in the AGQ and 
the balance of that coverage (i.e. body structures, body functions, activity and participation). 
Currently, the social context of disability is under represented in PRO instruments (over 
emphasis on items that measure body structures and functions) [9]. By contrast, the AGQ 
provides good breadth of coverage of ICF components from both an individual (body 
structures, body functions and activities) and societal (participation) perspective. This is 
important, if PRO instruments are to serve the purpose of complementing clinical outcomes 
(rather than duplicating them from the patients’ perspective).  
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This study used a subsample of PRO instruments identified in a wider study assessing 
instrument quality. One of the reasons for this was the necessity to construct our item pool 
from instruments in the public domain. This inevitably resulted in the exclusion of valid and 
reliable instruments with relevant content. This limitation is unlikely to have had a 
detrimental effect on the content coverage of our item pool due to the diversity of the 
instruments included in this study and to the breadth of content and theoretical coverage of 
their items.  
 
We do not yet know the psychometric properties of the AGQ and which, if any, items will 
be dropped as a result of a formal validation and assessment of its psychometric properties. 
However, this is true of all pre-validation work and does not detract from the importance of 
reporting this systematic approach to pre-validation methodology. The content of the AGQ 
has been designed to be acceptable to all participants in a future RCT evaluating the 
effectiveness of glaucoma screening (i.e. applicable to people with and without a diagnosis 
of glaucoma). In addition, we anticipate that the optimal AGQ will be able to discriminate 
between different stages of glaucoma severity.  By systematically accounting for all items 
dropped after the item generation phase, our method ensures that the AGQ is fit for 
validation. The discriminative capabilities (responsiveness) of the AGQ will be established 
following formal validation with a large patient sample and will be reported elsewhere.  
 
Conclusions  
This study presents a novel methodology for developing a new PRO instrument, based on 
three sources: literature that reports what is important to patients (content coverage) and 
which provides a body of empirical evidence for item generation; theoretically coherent 
framework (theoretical coverage); and patients’ experience of completing the instrument 
(acceptability). We recommend this to researchers as a transparent and replicable method 
that will enhance the likelihood that new PRO instruments will be appropriate to the 
research context in which they are used, acceptable to research participants and likely to 
generate valid data. 
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Figures 
Figure 1 - methodological development of AGQ flowchart 
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Tables 
Table 1: 5-step PRO development methodology 
Step 1 Item generation:  
a. Systematic identification of existing PRO instruments meeting explicit 
eligibility criteria.  
b. Selection of additional instruments (e.g. generic instruments) to be 
administered alongside the new PRO instrument.  
c. All items from the identified instruments form the initial ‘item pool’ (to 
which Steps 2-5 are applied). 
Step 2 Item de-duplication. Items are discarded if:  
A) They are literal duplications (identically worded items, or duplication of 
item content) 
B) Their content differs only by timeframe or attribution to a condition of 
interest (e.g. do you have difficulty…because of your condition) 
C) Their content overlaps with generic measures to be administered alongside 
new instrument (e.g. SF-36)  
Step 3 Item reduction:  
D) Macro level: items discarded if associated with content themes (dimensions 
of health) that are not appropriate for inclusion in the new instrument (e.g. 
treatment satisfaction) 
E) Micro level: application of explicit, study-relevant criteria to select items 
for inclusion in draft instrument (actual content area) 
Step 4 Assessment of content coverage against a relevant pre-existing theoretical 
framework (revisit 3E if content coverage suboptimal) 
Step 5 Exploratory pilot work with target population to assess comprehensibility, 
acceptability, relevance and answerability in order to inform instrument 
refinement (item removal &/or re-wording) (e.g.‘think aloud’ study, focus 
groups) 
 
Table 2: Selected instruments for inclusion in the item pool   
Activities of daily vision scale [15] TSS-IOP [16]  
 Glaucoma Symptom Scale [17] Turano [18]  
Glaucoma Quality of Life – 15 [19] Uenishi  [20]  
IND VFQ 33 [21]  Visual Activities Questionnaire [22] 
Impact of Vision Impairment  [23] VF-14  [24] 
Mills [25]  LVQOL  [26] 
Viswanathan [27]  Adapted General Well-Being Index [28]  
NEI-VFQ 25  [29] CES-D  [30] 
Odberg symptom items [31]  SWED-QUAL  [32]  
QOLVFQ  [33]  SUMI [34] 
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Table 3: Extract from item pool illustrating presentation of item-level data 
Item 
No Item Response Instrument 
257 
Do objects ever 
suddenly appear when 
you should have 
noticed them before? 
1=no, 2=uncertain, 3=yes MILLS 1986  
258 
Does your vision give 
you any difficulty (even 
with glasses) with 
seeing objects coming 
from the side?  
1=none, 2=a little bit, 3=some, 
4=quite a lot, 5=severe, 0=do 
not perform for nonvisual 
reasons  
GQL-15 
259 
Because of your 
eyesight, how much 
difficulty do you have 
noticing objects off to 
the side while you are 
walking along? 
1=no difficulty at all, 2=a little 
difficulty, 3=moderate difficulty, 
4=extreme difficulty, 5= stopped 
doing this because of your 
eyesight, 6=stopped doing this 
for other reasons or not 
interested in doing this  
NEI VFQ-
25 
260 
I have trouble noticing 
things in my peripheral 
vision.  
never, rarely, sometimes, often, 
always  VAQ 
 
 
Table 4: Extract from item pool illustrating presentation of items 2, 3, 4, 5, before 
literal de-duplication 
 
Item 
No. Item Response Instrument 
2 In general would you 
say your health is...  
1-4 scale response, higher scores 
indicating more optimistic 
views. 
QOLVFQ 
3 
In general, would you 
say your overall health 
is… 
1=Excellent, 2=very good, 
3=good, 4=fair, 5=poor. 
NEI VFQ-
25 
4 In general would you 
say your health is: 
1=very good, 2=fairly good, 
3=fair, 4=rather bad, 5=very bad 
SWED-
QUAL 
5 In general would you 
say your health is:  
Excellent, very good, good, fair, 
poor SF-36 
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Table 5: Extract from item pool illustrating presentation of items 2, 3, 4, 5, after literal 
de-duplication (phase A)  
Item 
No. Item Response Instrument 
2 1-4 scale response, higher scores indicating more optimistic views. QOLVFQ 
3 1=Excellent, 2=very good, 3=good, 4=fair, 5=poor. 
NEI VFQ-
25 
4 1=very good, 2=fairly good, 3=fair, 4=rather bad, 5=very bad 
SWED-
QUAL 
5 
In general would 
you say your 
[overall] health is: 
Excellent, very good, good, fair, 
poor SF-36 
 
 
 
Table 6: Phase B - Example of de-duplication on basis of differing timescale 
and/or attribution to eyesight  
Item 
No. Item Response Instrument 
153 During the past week I felt lonely. 
0= rarely or none of the time 
(less than 1 day); 1=some or a 
little of the time (1-2 days); 2= 
occasionally or a moderate 
amount of the time (3-4 days); 
3= most or all of the time (5-7 
days) 
CES-D 
154 Do you feel alone? 0=no, 2=sometimes, 4=yes UENISHI (2003) 
68 
 In the past month have 
you felt lonely or 
isolated because of 
your eyesight? 
not at all, very rarely, a little of 
the time, a fair amount of the 
time, a lot of the time, all of the 
time. 
IVI  
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Table 7: Extract from item pool after Phase C 
Item 
No. Item Response Instrument 
594 
During a typical day 
does your health limit 
bathing or dressing 
yourself?   
Yes, limited a lot; yes, limited a 
little;  No, not limited at al. SF-36 
 
597 
 
Is your health today 
good enough that you 
can dress yourself?  
 
1=yes without difficult, 2=yes, 
with some difficulty, 3=yes, with 
great difficulty, 4= no, not at all. 
SWED-
QUAL 
598 Can you change clothes by yourself?  Yes/with difficulty/no SUMI 
 
601 
 
Do you have difficulty 
dressing because of 
your visual problems?  
No/occasionally/frequently SUMI 
 
 
 
Table 8: Four of the items removed during Phase E 
Item 
No. Item Response 
553 
When you write sentences in 
vertical lines, does it lean to 
either direction? 
No/occasionally/frequently 
566 
Because of your vision how 
much problem do you have in 
locking and unlocking the 
door? 
Not at all, a little, quite a bit, a lot, cannot 
do because of my sight.  
569 Do you have difficulty, even 
with glasses doing decorating? 
(Yes/No/Not applicable)  If yes, how 
much difficulty do you currently have? 
(A little=1; A moderate amount=2; A 
great deal=3, Are you unable to do the 
activity=4?) 
572 Do you have difficulty with 
chopsticks?  No/occasionally/frequently 
 
 
 
Additional files 
Additional file 1 – Linking AGQ content to ICF 
 2A) De-duplication: Literal 
duplication  n  = 91 
2B) De-duplication: Timescale 
&/or attribution  n = 225 
2C) Content overlap 
with SF-36  n  = 48 
 
3D) Item reduction :  
Macro level  n  = 70 
 
3E) Item reduction:   
Micro level  n  = 208 
Items in draft AGQ    n = 83 
5) Refinement following 
exploratory work with target 
population ??????????????
study  n  = 15 
 
Pre-validation  prototype AGQ  n = 68 
 
  
  
 
4) Assessment of theoretical 
coverage (ICF components) n = 0 
 
1) Item generation: Eligible items  n  = 725 
 
Figure 1
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